IN THE CLAIMS

Please amend the claims as follows:

1.- (Previously Presented) A sulfonamide of general formula (Ia),



(Ia)

wherein

R^1 represents a $-NR^7R^8$ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^2, R^3, R^4, R^5 and R^6, identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a $-NR^9R^{10}$ group,

R^7 and R^8, identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical,

with the proviso that R^8 and R^9 are not hydrogen at the same time, and if one of them,

R^8 or R^9, is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_1-C_4 aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms,

or

R^7 and R^8, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^9 and R^{10}, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R^9 and R^{10}, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A and B, identical or different, each represent a saturated or unsaturated, linear or branched aliphatic radical, optionally at least mono-substituted

or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic cycloalkyl ring, optionally at least mono-substituted

and

n is 0,

a stereoisomer thereof, an enantiomer thereof, a diasteromer thereof, a racemate thereof, a pharmaceutically acceptable salt thereof, or mixtures thereof.

2. (Previously Presented) The compound according to claim 1, wherein R^1 represents a $-NR^7R^8$ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing 5- or 6-membered cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- or 6-membered.

3.- (Previously Presented) The compound according to claim 1 wherein R^2, R^3, R^4, R^5 and R^6, identical or different, each represent hydrogen, F, Cl, Br, cyano, nitro, a linear or branched C_{1-6} alkyl radical, a linear or branched C_{2-6} alkenyl radical, a linear or branched C_{2-6} alkynyl radical, a linear or branched C_{1-6} alkoxy, a linear or branched C_{1-6} alkylthio, hydroxy, trifluoromethyl, a saturated or unsaturated C_{3-8} cycloaliphatic radical, a linear or branched C_{1-6} alkylcarbonyl radical, phenylcarbonyl or an $-NR^9R^{10}$ group.

4.- (Previously Presented) The compound according to claim 1, wherein R^7 and R^8, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_{1-10} alkyl radical, a linear or branched, optionally at least mono-substituted,C_{2-10} alkenyl radical, or a linear or branched, optionally at least mono-substituted, C_{2-10} alkynyl radical or

R^7 and R^8, together with the bridging nitrogen form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclicc cycloaliphatic ring system, whereby the rings of the ring system are 5- 6- or 7-membered.

5.- (Previously Presented) The compound according to claim 4, wherein R^7 and R^8, identical or different, each represent hydrogen or a linear or branched C_{1-10} alkyl radical or

R^7 and R^8, together with the bridging nitrogen atom form a radical chosen from the group consisting of



,


,




,


and


wherein R^{20}, if present, is hydrogen, a linear or branched C_1-C_6 alkyl radical or a benzyl radical.

6.- (Previously Presented) The compound according to claim 1, wherein R^9 and R^{10}, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1-C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2-C_{10} alkenyl radical or a linear or branched, optionally at least mono-substituted C_2-C_{10} alkynyl radical or

R^9 and R^{10}, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclicc cycloaliphatic ring system whereby the rings of the ring system are 5- 6- or 7-membered.

7.- (Previously Presented) The compound according to claim 6, wherein R^9 and R^{10}, identical or different, each represent hydrogen or a linear or branched C_1-C_{10} alkyl radical, or

R^9 and R^{10}, together with the bridging nitrogen atom form a radical chosen from a group consisting of



,


,




,


and


wherein R^{20}, if present, is hydrogen, a linear or branched C_1-C_6 alkyl radical or a benzyl radical.

8.- (Previously Presented) The compound according to claim 1, wherein A and B, identical or different, each represent a linear or branched C_1-C_6 alkyl radical, a linear or branched C_2-C_6 alkenyl radical or a linear or branched C_2-C_6 alkynyl radical, or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring.

9.- (Previously Presented) The compound to claim 1, which is selected from a group consisting of

[1] 1-Cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-5-nitro-1H-indole,

[2] 5-Chloro-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole,

[3] 5-Amino-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole,

[4] 1-Cyclohexanesulfonyl-5-fluoro-3-(1,2,3,5,8,8a-hexahydro-indolizine-7-yl)-1H-indole hydrochloride,

a salt thereof, and a solvate thereof.

10.- (Previously Presented) A sulfonamide compound of general formula (Ib),



(Ib)

wherein

R^1 is a $-NR^7R^8$ radical,

R^2, R^3, R^4, R^5 and R^6, identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a $-NR^9R^{10}$ group,

R^7 and R^8, identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched C_{1-4} aliphatic radical,

R^9 and R^{10}, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or

R^9 and R^{10}, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A and B, identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical

or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

and

n is 0;

a stereoisomer thereof, an enantiomer thereof, a diasteromer thereof, a racemate thereof, a pharmaceutically acceptable salt thereof, or mixtures thereof.

11.- (Previously Presented) The compound according to claim 10, wherein R^2, R^3, R^4, R^5 and R^6, identical or different, each represent hydrogen, F, Cl, Br, cyano, nitro, a linear or branched C_1-C_6 alkyl radical, a linear or branched C_2-C_6 alkenyl radical, a linear or branched C_2-C_6 alkynyl radical, a linear or branched C_1-C_6-alkoxy, a linear or branched C_1-C_6 -alkylthio, hydroxy, trifluoromethyl, a saturated or unsaturated C_3-C_8 cycloaliphatic radical, a linear or branched C_1-C_6-alkylcarbonyl radical, phenylcarbonyl or an $-NR^9R^{10}$ group.

12.- (Previously Presented) The compound according to claim 10, wherein R^7 and R^8, identical or different, wherein R^7 and R^8, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1-C_4 alkyl radical with the proviso that R^7 and R^8 are not hydrogen at the same time.

13.- (Previously Presented) The compound according to claim 10, characterized in that R^9 and R^{10}, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1-C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2-C_{10} alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2-C_{10} alkynyl radical or

R^9 and R^{10}, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclicc cycloaliphatic ring system, whereby the rings of the ring system are 5- 6- or 7-membered.

14.- (Previously Presented) The compound according to claim 13, wherein R^9 and R^{10}, identical or different, each represent hydrogen or a linear or branched C_1-C_{10} alkyl radical, or

R^9 and R^{10}, together with the bridging nitrogen atom form a radical chosen from a group consisting of



,


,




,


and


wherein R^{20}, if present, represents hydrogen, a linear or branched C_1-C_6 alkyl radical or a benzyl radical.

15.- (Previously Presented) The compound according to claim 10, wherein A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring.

16.- (Previously Presented) A process for obtaining a sulfonamide compound of general formula (Ia) according to claim 1, wherein at least one compound of general formula (II), or a protected compound thereof,



(II)

wherein A and B have the meaning according to claim 1 and X is a leaving group, is reacted with at least one substituted indole of general formula (III)



(III)

wherein R^1-R^6 and n have the meaning according to claim 1, or a protected compound thereof, and, if necessary, the protective groups are removed.

17.- (Previously Presented) A process for obtaining a sulfonamide compound of general formula (Ia) according to claim 1, wherein one or more substituents R^2, R^3, R^4, R^5 or R^6 represent a nitro group, and wherein a sulfonamide compound of general formula (Ia) is reduced to a sulfonamide compound of corresponding general formula (Ia), wherein one or more substituents R^2, R^3, R^4, R^5 or R^6 represent an amino group.

18.- (Previously Presented) A process for preparing a salt of the compound of formula (Ia) according to claim 1, the process comprising reacting at least one compound of the general formula (Ia) with a mineral acid or organic acid in a solvent to form the salt of the compound of formula (Ia).

19.- (Previously Presented) A composition comprising at least one compound according to claim 1 and one or more pharmacologically acceptable excipients.

20.- (Cancelled).

21. - (Currently Amended) A method for treating a disease or disorder selected from the group consisting of cognitive memory disorders, senile dementia processes, Alzheimer's Disease, Parkinson's Disease, dementia, psychosis, disorders of the CNS and schizophrenia in a subject in need thereof by regulating ~~of regulating~~ a 5-HT_6 receptor in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to ~~regulate a 5-HT_6 receptor~~ to treat the disease or disorder in the subject.

22.- (Previously Presented) A method of treating a disorder or disease related to food intake in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder or disease in the subject.

23.- (Previously Presented) A method for regulating appetite in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to regulate appetite in the subject.

24.- (Previously Presented) A method for regulating body weight in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to regulate body weight in the subject.

25.- (Previously Presented) A method of treating obesity in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat obesity in the subject.

26.- (Previously Presented) A method of treating bulimia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat bulimia in the subject.

27.- (Previously Presented) A method for treating anorexia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat anorexia in the subject.

28.- (Previously Presented) A method for treating cachexia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat cachexia in the subject.

29.- (Previously Presented) A method for treating type II diabetes in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat type II diabetes in the subject.

30.- (Previously Presented) A method of treating a gastrointestinal tract disorder in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.

31.- (Previously Presented) A method for treating irritable bowel syndrome in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat irritable bowel syndrome in the subject.

32.- (Previously Presented) A method for treating anxiety in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat anxiety in the subject.

33.- (Previously Presented) A method for treating depression in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat depression in the subject.

34.- (Previously Presented) A method for treating bipolar disorder in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.

35. - (Previously Presented) A method for treating cognitive memory disorder in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.

36.- (Previously Presented) A method for treating senile dementia processes in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the senile dementia process in the subject.

37.- (Previously Presented) A method for treating Alzheimer's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disease in the subject.

38.- (Previously Presented) A method for treating Parkinson's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disease in the subject.

Claims 39-40 (Cancelled)

41.- (Currently Amended) A method for treating dementia ~~dimensia~~ in which a cognitive deficit predominates in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the dementia ~~dimensia~~ in the subject.

42.- (Previously Presented) A method for treating psychosis in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat psychosis in the subject.

43.- (Previously Presented) A method for treating infantile hyperkinesia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat infantile hyperkinesia in the subject.

44.- (Previously Presented) A method for treating a disorder of the central nervous system in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.

45.- (Previously Presented) A method for treating schizophrenia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat schizophrenia in the subject.

46.- (Previously Presented) A method of enhancing cognitive ability in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to enhance cognitive ability in the subject.

47. (Previously Presented) A composition comprising at least one compound according to claim 9 and at least one or more of pharmacologically acceptable excipients.

48.- (Cancelled)

49.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament~~ ~~for~~ A method for treating a disease or disorder selected from the group consisting of cognitive memory disorders, senile dementia processes, Alzheimer's Disease, Parkinson's Disease, dementia, psychosis, disorders of the CNS and schizophrenia in a subject in need thereof by regulating 5-HT_6 receptor ~~regulation,~~ the method comprising administering at least one compound according to Claim 10 in an amount sufficient to treat the disease or disorder.

50.- (Currently Amended)~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake~~ A method of treating a disorder or disease related to food intake in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the disorder or disease in the subject .

51.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the regulation of appetite~~ A method for regulating appetite in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to regulate appetite in the subject.

52.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the maintenance, increase or reduction of body weight~~ A method for regulating body weight in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to regulate body weight in the subject.

53.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity~~ A method of treating obesity in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat obesity in the subject.

54.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia~~ A method of treating bulimia in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat bulimia in the subject.

55.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia~~ A method for treating anorexia in a subject in need thereof, the method comprising

administering at least one compound according to claim 10 in an amount sufficient to treat anorexia in the subject.

56.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia~~ A method for treating cachexia in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat cachexia in the subject.

57.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity~~ A method for treating type II diabetes in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat type II diabetes in the subject.

58.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders~~ A method of treating a gastrointestinal tract disorder in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the disorder in the subject.

59.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome~~ A method for treating irritable bowel syndrome in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat irritable bowel syndrome in the subject.

60.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety~~ A method for treating anxiety in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat anxiety in the subject.

61.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of depression~~ A method for treating depression in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat depression in the subject.

62.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders~~ A method for treating bipolar disorder in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the disorder in the subject.

63.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders~~ A method for treating cognitive memory disorder in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the disorder in the subject.

64.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes~~ A method for treating senile dementia processes in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the senile dementia process in the subject.

65.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease~~ A method for treating Alzheimer's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the disease in the subject.

66.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease~~ A method for treating Parkinson's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the disease in the subject.

Claims 67-68 (Cancelled)

69.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates~~ A method for treating dementia in which a cognitive deficit predominates in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the dementia in the subject.

70.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis~~ A method for treating psychosis in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat psychosis in the subject.

71.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder)~~ A method for treating infantile hyperkinesia in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat infantile hyperkinesia in the subject.

72.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system~~ A method for treating a disorder of the central nervous system in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat the disorder in the subject.

73.- (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia~~ A method for treating schizophrenia in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to treat schizophrenia in the subject..

74. - (Currently Amended) ~~The use of at least one compound according to claim 10 for the manufacture of a medicament for cognitive enhancement~~ A method of enhancing cognitive ability in a subject in need thereof, the method comprising administering at least one compound according to claim 10 in an amount sufficient to enhance cognitive ability in the subject.

75. (Previously Presented) The compound according to claim 1, wherein R^1 represents a NR^7R^8 radical or a radical chosen from the group consisting of



wherein, if present, the dotted line represents an optional chemical bond, and R^{19} represents hydrogen, a linear or branched C_1-C_6 alkyl radical or a benzyl radical, preferably hydrogen or a C_1-C_2 alkyl radical.

76. (Previously Presented) The compound according to claim 1, wherein R^2, R^3, R^4, R^5 and R^6, identical or different, each represent H, F, Cl, NO_2, NH_2 or a C_{1-2} alkyl radical.